For example, combined use of ALW-II-41-27 and WW437, a histone deacetylase inhibitor that could suppress phosphorylated EphA2 and EphA2 expression, results in remarkably increased effects on breast cancer cell growth and migration compared with either drug administered as monotherapy [87]. This evidence concerns the gene EPHA2 and breast carcinoma.